Quectel Announces New Generation 5G Release 17 Module Series to Address Growing 5G FWA and eMBB Markets
MWC BARCELONA – Quectel Wireless Solutions, a global IoT solutions provider, today announces the launch of its latest generation 5G New Radio (NR) module series, the RG650E and RG650V, both of which follow the 3GPP Release 17 standard. These industrial grade 5G modules deliver enhanced performance in data rates, capacity, power saving, and latency as well as ultra-reliability, better addressing the growing 5G fixed wireless access (FWA), enhanced mobile broadband (eMBB), and industrial automation markets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230226005190/en/
Quectel announces new generation 5G Release 17 module series to address growing 5G FWA and eMBB markets (Photo: Business Wire)
Based on the latest Snapdragon® X75 and X72 5G Modem-RF Systems from Qualcomm Technologies, Inc., the RG650E and RG650V series can work on both 5G non-standalone (NSA) and standalone (SA) modes. The RG650E supports a maximum bandwidth of 300 MHz in the sub-6GHz spectrum while the RG650V supports up to 200 MHz bandwidth. The adoption of Option 3x/ 3a/ 3 and Option 2 network architectures makes the modules backward compatible with global LTE and WCDMA networks.
Quectel also provides an RG650x-based System-on-Chip (SoC) solution with the latest Wi-Fi 7 technology, which significantly increases transfer speeds, reduces latency, and boosts overall network capacity for customer applications. Additionally, the module’s support of OpenWRT allows it to provide advanced networking features in a wider range of upstream ecosystem applications.
Integrated with a Quad-Core A55 processor, the RG650E and RG650V support 5G NR downlink carrier aggregation (CA), greatly improving data rates to meet the demand for super high data speeds in IoT verticals and applications, especially for FWA devices like CPE, home gateway, enterprise gateway, industrial router, mobile hotspot, eMBB terminals including high-definition live broadcast, AR/VR device, drone as well as industrial automation applications such as automated guided vehicles (AGV), remote control, and robot.
“We are excited to roll out the industry’s most advanced 5G NR modules based on the cutting-edge Snapdragon X75 and X72,” said Norbert Muhrer, President and CSO, Quectel Wireless Solutions. “Our latest 5G NR Release 17 modules feature unprecedented performance and significant advantages in communication capability. I believe they will provide an excellent Sub-6GHz, mmWave and Wi-Fi 7 solution for the growing 5G FWA and eMBB markets.”
“Snapdragon X75 and X72, the world’s first 5G Advanced-ready modem-RF system provides unparalleled features and capabilities for performance, power efficiency, and flexibility making it the ideal solution for various highly demanding applications and use cases,” said Gautam Sheoran, vice president, product management, Qualcomm Technologies, Inc. “We are excited to see Quectel adopting our new modem-RF systems to drive the next stage of 5G evolution in all key verticals including FWA, home getaways, Industrial IoT, and more.”
The RG650E and RG650V series supports Qualcomm® Location Suite with Qualcomm® GNSS HW Gen 9.v6 (Concurrent GPS, BeiDou, Galileo, GLONASS, NavIC, and QZSS). The integrated GNSS receiver greatly simplifies product design and provides quicker, more accurate, and more dependable positioning capability for applications in any environment. Additionally, they provide a wide range of interfaces such as USXGMII, PCIe, USB 2.0/ 3.0/ 3.1, PCM and supplementary functions including VoLTE and VoNR.
The Quectel 5G module offering is complemented by its range of antennas which help optimize connection efficiency and aid ease of installation of devices. These can be supplied pre-integrated with Quectel IoT modules to accelerate time to market and help eliminate commonly found integration issues.
Engineering samples of the RG650E and RG650V will be available for global markets in the first half of 2023. To learn more, visit the Quectel booth at MWC Barcelona 2023, Hall 5, Booth 5A20.
About Quectel
Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.
With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.
For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.
Snapdragon and Qualcomm are trademarks or register trademarks of Qualcomm Incorporated.
Snapdragon and Qualcomm branded products are products of Qualcomm Technologies, Inc. and/or its subsidiaries. Qualcomm patented technologies are licensed by Qualcomm Incorporated.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230226005190/en/
Contact information
Media:
Phil Rawcliffe, Head of Communications
phil.rawcliffe@quectel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 13:31:00 EET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 01:49:00 EET | Press release
Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive Officer, Lattice Semiconductor. The annual GSA Awards celebrate the accomplishments of the semiconductor indu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom